ATH 06Alternative Names: AFFITOPE® AT06A+adjuvant; AT06A; ATH06
Latest Information Update: 03 Aug 2015
At a glance
- Originator AFFiRiS
- Class Antihyperlipidaemics; Peptide vaccines; Synthetic vaccines
- Mechanism of Action LDL receptor antagonists; PCSK9 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Atherosclerosis
Most Recent Events
- 01 Jul 2015 Phase-I clinical trials in Atherosclerosis in Austria (SC) (NCT02508896)
- 20 Jun 2014 Preclinical trials in Atherosclerosis in Austria (SC)